The Effect of Anxiety and / or Depression to Morbidity and Mortality in Hospitalized Patients with Heart Failure  by Ataş, Umut Yavuz et al.
with angiographic incidence of % 0.15. The second most common anomaly was
anomalous origin of circumﬂex artery (originating from right coronary sinus/ RCA) in
19 patients (18.8%) with angiographic incidence of (0.1%) and the third was anom-
alous origin of right coronary artery (originating from left coronary sinus or LAD) in
18 patients (17.8%, 0.1%). Left main coronary artery or LAD originating right
coronary sinus or RCA was seen in 7 patients (6.9%, 0.04%) (Figure 2). Right
coronary artery agenesis was detected in 3 patients (2.9%, 0.013%), and coronary
interconnection was found 2 patients (1.9%, 0.011%). Fifty-seven patients had
coronary artery disease, eight patients presented with acute coronary syndrome. We
determined eight patients with heart failure, three patients with mitral valve regurgi-
tation, one patient with severe aortic regurgitation, one patient with ascending aorta
aneurysm, three patients with muscular bridge and two patients with coronary ectasia.
There was no additional cardiac pathology in twenty-six patients.
Dıscussıon: Angiographic recognition of these vessels is important because of their
clinical signiﬁcance in patients undergoing coronary angioplasty or cardiac surgery. In
general although the incidence of coronary anomalies in our study was less than the
results of previous studies, the pattern of coronary anomalies were similar to earlier
reports.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POST
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Introductıon: Anxiety is a disorder with unknown origins. Depression is severe
despondency and dejection and these feelings interfere with everyday life for two
weeks or longer. In this study of hospitalized patients with heart failure (HF), we have
investigated the effect of anxiety and/or depression on morbidity and mortality.
Materıals-Methods: We enrolled 102 patients with HF who were diagnosed by
a cardiologist with Class III-IV functional capacity, and for the other group we
enrolled 102 patients without HF but with chronic illness. We got approval from the
ethics committee. In our face to-face interviews with the patients and their relatives,
we obtained socio-demographic data. We applied "Hospital Anxiety and Depression
Scale" for them. We called them for a phone survey after they were discharged from
the hospital for six months. We inquired if the patients were alive or not, and if they
were re-hospitalized. We used T-Test, Mann-Whitney U test, Kruskalwallis and
ANOVA, Chi Square statistical methods. SPSS 20.0 program were used for analysis.
Results: There weren't any statistical differences between the patient group (PG) and
control group in terms of their age, sex, education, income, where they live, marital
status, if they have any children and their living arrangements (p¼0.101, 0.322,0.057,
0.209, 0.183, 0.085,0.104,0.422). In the PG, hospitalization rate and frequency in the last
year was signiﬁcantly higher (p¼0.000, 0.001). In the PG, anxiety and anxiety scale,
depression and depression scale were signiﬁcantly higher compared to the control group
(p¼0.001,0,002,0.003, 0.032). In the PG, number of patients who didn't feel well were
higher compared to the control group (p¼ 0.000). In the PG, there wasn't a relation
between anxiety and/or depression and the patients' age, sex, income, marital status or
their living arrangements (p¼0.425, 0.294, 0.537,0.897,0.492 and 0.476,0.906,0.828,
0.213,0.600). In the PG, there wasn't a signiﬁcant difference in Ejection fraction (EF),
length of illness and re-hospitalization rate between the patientswith andwithout anxiety
or depression however, re-hospitalization rate was higher in patients with depression
(¼0.015). After 6 months, the rate of depression and anxiety turned out be dramatically
higher in patients who hadHF and died (39.1%, 82.6%), comparedwith the patients who
had the same heart dysfunction but still alive (15.2%, 17.4%) (p¼0.012, p¼0.032).
Dıscussıon: In our study, 20.6% of HF patients in our hospital had depression.
According to the results we obtained, anxiety and /or depression negatively effect
morbidity and mortality, re-hospitalization rate and death occurrences in the next six
monthsIn HF patients with anxiety and depression, a multi-disciplinary approach must
be taken and a psychiatrist must be involved in their treatment.The comparison ﬁndings of patients with and without depression in the patient
group
Without
Depression
With
Depression p
MeanSD % MeanSD %
EF(%) 45.614.1 38.619.2 0.160
Disease Lenght 10.97.7 9.77.3 0.545
Rehospitali-
zation in
6 months
Yes n¼30 68.2 n¼14 31.8 0.015
No n¼51 87.9 n¼7 12.1
How do
thepatients
feel about their
health
Good-
Medium
n¼77 86.5 n¼12 13.5 0.000
Bad n¼4 30.8 n¼9 69.2
n: case number, SD: Standart Deviation, EF: Ejection Fraction
The comparison of the rate of depression between exitus and survive in 6
months in patient group
Without
Depression
With
Depression p
n % n %
After 6 m, are the
patients alive
Yes 67 84.8 12 15.2 0.012
No 14 60.9 9 39.1
m: months, n: case number
ERS C115
The comparison of the rate of anxiety between exitus and survive in 6 months
in the patient group
Without
Anxiety
With
Anxiety p
n % n %
After 6 m, are the
patients alive?
33 41.8 46 58.2 0.032
4 17.4 19 82.6
m:months, n:case number
Comparison of average MPV values of patient and control group
CONTROL GROUP PATIENT GROUP
Mean SD Mean SD p value
MPV 10,11 0,80 10,43 0,95 0.029
SD: Standard Deviation
Comparison of patient and control group with high MPV value
CONTROL GROUP PATIENT GROUP
MPV number % number % Chi Square p value
Normal 46 92 184 73,6 7,88 0.005
High 4 8 66 26,4
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Aim: Pericardial effusion (PE) is called that increase in the amount of ﬂuid between
the pericardium surrounding the heart. PE may be due to primary pericardial diseases,
or associated with different clinical situations such as malignancy, chronic renal
failure, cardiovascular diseases, infectious diseases. In our study, patients with PE
present in the Gaziantep region to evaluate the clinical characteristics and treatment.
Method: 132 patients, having PE on transthoracic echocardiography, admitted to the
cardiology clinic between January 2010 and January 2011, were retrospectively
reviewed data. Background, echocardiography, laboratory ﬁndings, and treatment of
the patients were recorded.
Results: The average age of the patients was 5117 (17-86) year. It was observed
with equal frequency in males and females (66/66). The most common primary
complaint of patients with PE were dispne (73.5%). Mild PE (<10 mm) on Echo-
cardiography was the most common (48.5%). The most common causes of PE were
a history of infectious diseases and heart failure. 21.2% of the patients underwent
pericardiocentesis. The most common only NSAIDs in patients undergoing medical
treatment (50%). Effusion disappeared pericardiocentesis, dialysis and medical treat-
ment in 105 patients (79.5%). Medical treatment of PE, an average of 3639.2
(6-190) days disappeared. Four patients died during the follow-up regardless of the
amount the effusion in the hospital.
Conclusıon: PE is developing in the process of many diseases. Of the patients in the
outpatient treatment may be sufﬁcient however, the etiology of PE is a major cause of
prognosis in chronic disease cases accompanied by close monitoring of patients is
important.
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Introductıon: 8–14 million people world wide are die due to diabetes, cardiovascular
diseases, cancer and many other chronic diseases. Also rapid change of lifestyle,
environmental conditions and due to stress factors prevalence especially of type 2
diabetes mellitus (diabetes) increased in developing countries. As it is known diabetic
patients CVD (Cardiovascular Disease) risk are 2-4 times higher than non-diabetic
individuals. In addition, DM is an important cardiovascular risk factor, and facilitates
the development of atherosclerosis by several mechanisms. Guidelines for diabetes
treatment recommend the routine use of aspirin in patients with diabetes mellitus
(DM) who have cardiovascular disease (CVD), those with at least one CVD risk
factor, and for anyone with DM who is >30 years of age or, if contraindicated, an
alternative antiplatelet agent. The aim of this study is; to evaluate the frequency of
ASA (Asetil salisilic asid) use in type 2 Diabetic patients with dyslipidemia, and to
examine the relationship between patients demographic data such as (gender, blood
pressure, body mass index, smoking&alcohol use) and their concominant disease like
CVD (Cardiovascular Disease), HT (Hypertension), CRF (Chronic renal failure), SVD
(Serebrovascular Disease).ext.
Materials and methods: In this observational study, we have included 910 type 2
diabetic and dislipidemic patients 25–87 years of age, who had at least one visit to our
diabetes and internal medicine outpatient clinic in the following periods: JanuaryC116 JACC Vo2012-November 2012. Aspirin use was asked to patients and then patient-records were
analysed for obtaining the other data.
Results: Of the participants, 35.8% (n¼326) were males and 64.2% (n¼584) were
females. The mean age was 57.27  10.00. Of the participants, 26.8% (n¼244) had
coronary artery disease, 62.3% (n¼567) had hypertension, 5.2% (n¼47), had cere-
brovascular disease, 14.6% patients (n¼133) had retinopathy and 6.2% (n¼56) had
thyroid disease. Our analysis has shown that ASA, as an antiplatelet agent were
prescribed to 38,6% of the type 2 diabetic and dislipidemic patients and 61,4% of the
patients were not using ASA. There was a statistically signiﬁcant difference between
genders in terms of current ASA use. Men were more likely to use ASA (43.3%),
compared to women (36%) (p <0.05). 10.2% (n¼93) of the patients, had stopped
using ASA. When we examined all the cases of patients, 5.7% (n¼52) stopped using
aspirin for medical reasons, 4.5% (n¼41) left for other reasons.
Conclusıons: Patients with type 2 diabetes and dislipidemia whose Framingham risk
scores (estimated 10-year Global CVD Risk) are high should be treated based on the
ATP-III (2004), CCS(2009), ESC (2007) guidelines. Despite the ADA guidelines they
are not always under antiplatelet treatment, especially for primary prevention. We
found signiﬁcant underuse of aspirin therapy among our study population. For the
prevention of diabetes complications, efforts towards increasing these rates of anti-
platelet prophylaxis are necessary.
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Objectıves: Platelet activity plays an important role in the pathogenesis of athero-
sclerotic vascular disease. Increase in platelet volume is correlated with the activity of
the platelet. It has been reported that mean platelet volume has increased before the
acute myocardial infarction. In our study, the difference between the mean platelet
volume were investigated in patients presenting with chest pain and those with
a diagnosis of acute coronary syndrome or not.
Materıals-Methods: 250 patients (63.2% male, mean age 63.3013.86) with the
diagnosis of acute coronary syndrome and treated in coronary intensive care unit were
evaluated. Patients were divided into three subgroups such as ST elevation (STEMI)
and non-ST elevation myocardial infarction (NSTEMI) and unstable angina pectoris
(USAP). Fifty patients (46% male, mean age 56.2615.18) who admitted to the
emergency department with chest pain but were not diagnosed with acute coronary
syndrome, were included in the study as a control group. Clinical evaluation was
performed and cardiac risk factors were recorded. In patients with acute myocardial
infarction blood samples for platelet count and mean platelet volume were taken into
tubes containing EDTA during hospital admissions and prior to the standard treatment
regimen but in the control group blood samples were taken into tubes containing
EDTA in the emergency clinic. The normal mean platelet volume values are between
7.8 to 11 fL values and values above 11.1 fL were accepted as high.
Results: Average MPV values in the patient group was statistically signiﬁcantly
higher than the control group (10.430.80 and 10.110.95 ﬂ, p¼0.029). In the 26.4%
of patient group and 8% of control group, MPV values were above the normal
( 11,1) (p¼0.005). There was no signiﬁcant difference between MPV values of
NSTEMI, STEMI, and USAP groups (p¼0.316). The mean platelet count was lower
in the patient group but no statistically signiﬁcant difference was observed compared
to the control group (230103/mm3 and 246103/mm3, p¼0.127). Cardiac risk
factors such as diabetes mellitus was signiﬁcantly correlated with the mean MPV
values (10.340.91 in those without diabetes, 10.661.03 in those with diabetes,
p¼0.019).
Conclusıons: The mean platelet volume was signiﬁcantly higher in the acute phase of
coronary heart disease. Although not statistically signiﬁcant, decrease in platelet
counts observed during the acute phase. The presence of diabetes, independent of
other factors, inﬂuence the size of the platelet.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
